OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Jaap A. van Doesum, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2645-2655
Open Access | Times Cited: 21
Jaap A. van Doesum, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2645-2655
Open Access | Times Cited: 21
Showing 21 citing articles:
Current understanding and management of CAR T cell-associated toxicities
Jennifer N. Brudno, James N. Kochenderfer
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 501-521
Closed Access | Times Cited: 41
Jennifer N. Brudno, James N. Kochenderfer
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 501-521
Closed Access | Times Cited: 41
Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice
Essy Mozaffari, Aastha Chandak, Robert Gottlieb, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 12, pp. 1626-1634
Open Access | Times Cited: 33
Essy Mozaffari, Aastha Chandak, Robert Gottlieb, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 12, pp. 1626-1634
Open Access | Times Cited: 33
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Jon Salmanton‐García, Francesco Marchesi, Francesca Farina, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102553-102553
Open Access | Times Cited: 8
Jon Salmanton‐García, Francesco Marchesi, Francesca Farina, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102553-102553
Open Access | Times Cited: 8
The Efficacy of Chimeric Antigen Therapy in Viral Infectious Diseases: A Systematic Review of Randomized Controlled Trials
Hossein Hatami, Elnaz Ataei, Mohammad Javad Nasiri, et al.
Turkish Journal of Immunology (2025) Vol. 12, Iss. 3, pp. 84-91
Open Access
Hossein Hatami, Elnaz Ataei, Mohammad Javad Nasiri, et al.
Turkish Journal of Immunology (2025) Vol. 12, Iss. 3, pp. 84-91
Open Access
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Tobias Lahmer, Jon Salmanton‐García, Francesco Marchesi, et al.
Infection (2024) Vol. 52, Iss. 3, pp. 1125-1141
Open Access | Times Cited: 4
Tobias Lahmer, Jon Salmanton‐García, Francesco Marchesi, et al.
Infection (2024) Vol. 52, Iss. 3, pp. 1125-1141
Open Access | Times Cited: 4
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
Giuseppe Rossi, Jon Salmanton‐García, Chiara Cattaneo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 98-110
Open Access | Times Cited: 10
Giuseppe Rossi, Jon Salmanton‐García, Chiara Cattaneo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 98-110
Open Access | Times Cited: 10
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
Maeve O’Reilly, Lorna Neill, Simon M. Collin, et al.
HemaSphere (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Maeve O’Reilly, Lorna Neill, Simon M. Collin, et al.
HemaSphere (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill
Paschalis Evangelidis, Nikolaos Evangelidis, Panagiotis Kalmoukos, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 5, pp. 4787-4802
Open Access | Times Cited: 3
Paschalis Evangelidis, Nikolaos Evangelidis, Panagiotis Kalmoukos, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 5, pp. 4787-4802
Open Access | Times Cited: 3
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
Pellegrino Musto, Jon Salmanton‐García, Nicola Sgherza, et al.
Hematological Oncology (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 9
Pellegrino Musto, Jon Salmanton‐García, Nicola Sgherza, et al.
Hematological Oncology (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 9
Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb
Evlampia Strongyli, Paschalis Evangelidis, Ioanna Sakellari, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 591-591
Open Access | Times Cited: 2
Evlampia Strongyli, Paschalis Evangelidis, Ioanna Sakellari, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 591-591
Open Access | Times Cited: 2
COVID‐19 in hematopoietic stem‐cell transplant recipients: A systematic review and meta‐analysis of clinical characteristics and outcomes
Bruno Azevedo Randi, Hermes Ryoiti Higashino, Vinícius Ponzio da Silva, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 6
Closed Access | Times Cited: 6
Bruno Azevedo Randi, Hermes Ryoiti Higashino, Vinícius Ponzio da Silva, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 6
Closed Access | Times Cited: 6
Impact of COVID‐19 monoclonal antibodies on outcomes of COVID‐19 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients
E Hahn, Hong Li, Craig S. Sauter, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 4
Open Access | Times Cited: 1
E Hahn, Hong Li, Craig S. Sauter, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 4
Open Access | Times Cited: 1
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
Anne M. Spanjaart, Per Ljungman, Gloria Tridello, et al.
Leukemia (2024) Vol. 38, Iss. 9, pp. 1985-1991
Open Access | Times Cited: 1
Anne M. Spanjaart, Per Ljungman, Gloria Tridello, et al.
Leukemia (2024) Vol. 38, Iss. 9, pp. 1985-1991
Open Access | Times Cited: 1
Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience
Elisabetta Xue, Gianluca Scorpio, Annalisa Ruggeri, et al.
Current Research in Translational Medicine (2023) Vol. 71, Iss. 3, pp. 103402-103402
Open Access | Times Cited: 2
Elisabetta Xue, Gianluca Scorpio, Annalisa Ruggeri, et al.
Current Research in Translational Medicine (2023) Vol. 71, Iss. 3, pp. 103402-103402
Open Access | Times Cited: 2
Outcomes and risk factors of SARS‐CoV ‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy
Xibin Xiao, Panpan Chen, Yadi Zhong, et al.
Cancer Medicine (2023) Vol. 12, Iss. 22, pp. 20838-20846
Open Access | Times Cited: 2
Xibin Xiao, Panpan Chen, Yadi Zhong, et al.
Cancer Medicine (2023) Vol. 12, Iss. 22, pp. 20838-20846
Open Access | Times Cited: 2
New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs
Wenyi Zhang, Lecheng Xiao, D. Li, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Wenyi Zhang, Lecheng Xiao, D. Li, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
COMPARING THE EFFECTIVENESS AND SAFETY OF CASIRIVIMAB/IMDEVIMAB WITH BAMLANIVIMAB IN PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Maryam Karimi Babaahmadi, Mojhgan Mohajeri Iravani, Amirhossein Orandi, et al.
Studies in Medical Sciences (2024) Vol. 35, Iss. 4, pp. 250-264
Closed Access
Maryam Karimi Babaahmadi, Mojhgan Mohajeri Iravani, Amirhossein Orandi, et al.
Studies in Medical Sciences (2024) Vol. 35, Iss. 4, pp. 250-264
Closed Access
Mitigating and managing infection risk in adults treated with CAR T-cell therapy
Nadeem Tabbara, M. Veronica Dioverti, Tania Jain
Hematology (2024) Vol. 2024, Iss. 1, pp. 116-125
Closed Access
Nadeem Tabbara, M. Veronica Dioverti, Tania Jain
Hematology (2024) Vol. 2024, Iss. 1, pp. 116-125
Closed Access
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA ‐EPIFLUEHA Report
Jon Salmanton‐García, Francesco Marchesi, Milan Navrátil, et al.
American Journal of Hematology (2024) Vol. 100, Iss. 3, pp. 358-374
Open Access
Jon Salmanton‐García, Francesco Marchesi, Milan Navrátil, et al.
American Journal of Hematology (2024) Vol. 100, Iss. 3, pp. 358-374
Open Access
On a collision course: SARS-CoV-2 variants and CAR T cells
Jeffery J. Auletta
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2643-2644
Open Access
Jeffery J. Auletta
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2643-2644
Open Access
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report
Vera Radici, Cinzia Giagulli, Eugenia Accorsi Buttini, et al.
Frontiers in Transplantation (2023) Vol. 2
Open Access
Vera Radici, Cinzia Giagulli, Eugenia Accorsi Buttini, et al.
Frontiers in Transplantation (2023) Vol. 2
Open Access
